Evidence map›Paper›PMID 32469918›Full record

ArticlePloS one2020

Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates.

Massih Khorvash, Nick Blinov, Carol Ladner-Keay, Jie Lu, Judith M Silverman, Ebrima Gibbs, Yu Tian Wang, Andriy Kovalenko, David Wishart, Neil R Cashman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Massih KhorvashDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Nick BlinovDepartment of Mechanical Engineering, Edmonton, Alberta, Canada.
Carol Ladner-KeayNational Research Council of Canada, Edmonton, Alberta, Canada.
Jie LuUniversity of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada.
Judith M SilvermanUniversity of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada.
Ebrima GibbsUniversity of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada.
Yu Tian WangUniversity of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada.
Andriy KovalenkoDepartment of Mechanical Engineering, Edmonton, Alberta, Canada.ORCID 0000-0001-5033-4314
David WishartNational Research Council of Canada, Edmonton, Alberta, Canada.
Neil R CashmanDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-0080-1006
University of British Columbia · CANational Research Council Canada · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligomeric amyloid β (Aβ) is currently considered the most neurotoxic form of the Aβ peptide implicated in Alzheimer's disease (AD). The molecular structures of the oligomers have remained mostly unknown due to their transient nature. As a result, the molecular mechanisms of interactions between conformation-specific antibodies and their Aβ oligomer (AβO) cognates are not well understood. A monoclonal conformation-specific antibody, m5E3, was raised against a structural epitope of Aβ oligomers. m5E3 binds to AβOs with high affinity, but not to Aβ monomers or fibrils. In this study, a computational model of the variable fragment (Fv) of the m5E3 antibody (Fv5E3) is introduced. We further employ docking and molecular dynamics simulations to determine the molecular details of the antibody-oligomer interactions, and to classify the AβOs as Fv5E3-positives and negatives, and to provide a rationale for the low affinity of Fv5E3 for fibrils. This information will help us to perform site-directed mutagenesis on the m5E3 antibody to improve its specificity and affinity toward oligomeric Aβ species. We also provide evidence for the possible capability of the m5E3 antibody to disaggregate AβOs and to fragment protofilaments.

Indexed as

Protein MultimerizationAmino Acid SequenceAmyloid beta-PeptidesAntibodies, MonoclonalProtein BindingProtein Structure, QuaternaryAmyloid beta-PeptidesAntibodies, Monoclonal

Identifiers

PMID32469918
PMCPMC7259632
OpenAlexW3032179163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.